6 novembre 2025

Each year, the Federal Office of Public Health reviews one third of the medicinal products listed on the List of Pharmaceutical Specialties (Spezialitätenliste, SL) to assess their efficacy, appropriateness and cost-effectiveness (Kriterien der Wirksamkeit, Zweckmässigkeit und Wirtschaftlichkeit, WZW criteria). As part of this year’s review, the prices of almost 300 medicinal products were reduced by an average of twelve per cent. This is expected to lead to savings of around 65 million Swiss francs. At the same time, price reductions were exceptionally waived for 55 medicinal products to strengthen supply security.

For more information, see here.